Remove tag
article thumbnail

Can gene therapies for haemophilia defend their high price tags?

Pharmaceutical Technology

The program was put on hold in December 2020 following a patient report, but this was lifted in April 2021. million price tag. The post Can gene therapies for haemophilia defend their high price tags? CSL Behring has a commercialisation and license agreement to develop EtranaDez. million ($1.8 million at the time).

111
111
article thumbnail

Ultimovacs bags orphan drug tag for mesothelioma vaccine

Pharmaceutical Technology

The FDA decision follows a similar designation for the vaccine UV1 against malignant melanoma in December 2021.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Pear claims breakthrough tag for alcohol use disorder DTx

pharmaphorum

The company – which is in the process of going public via a merger with special purpose acquisition company (SPAC) Thimble Point – has predicted it will make around $4 million from its DTx portfolio in full-year 2021. The post Pear claims breakthrough tag for alcohol use disorder DTx appeared first on.

59
article thumbnail

FDA slammed over Aduhelm OK as Biogen takes heat for $56k price tag

pharmaphorum

— Dr. Patrizia Cavazzoni (@FDACDERDirector) June 7, 2021. — Brad Loncar (@bradloncar) June 7, 2021. The post FDA slammed over Aduhelm OK as Biogen takes heat for $56k price tag appeared first on. If benefit is not verified, we can act to remove the drug from the market.

article thumbnail

2021 Highlights of Chronic Care Medicine

PharmD Live

Virtual care, normalized by the pandemic, is now common practice for providers and patients, especially at the primary care level–a boon in 2021 for underserved chronic care populations. Aduhelm was approved by the FDA in 2021 with clinical trials outcome data indicating the potential to slow the accumulation of amyloid plaques.

article thumbnail

Widespread Implementation of Long-Acting PrEP for HIV May Be Stifled By High Price Tag, Say Researchers

Pharmacy Times

Following the approval of cabotegravir in 2021, governments and donor agencies in low- and middle-income countries are contemplating replacing oral pre-exposure prophylaxis or augmenting the approach with long-acting treatment.

49
article thumbnail

Global (68M) cardiomyopathies market projected to grow to $9.63bn by 2031

Pharmaceutical Technology

of sales in 2021 and 2031 respectively. The US is set to dominate the cardiomyopathy landscape because of the country’s high prevalence of dilated cardiomyopathy (DCM) relative to the other markets in the 7MM, as well as the higher price tag on US-marketed therapeutics. of global cardiomyopathies sales in 2021 and 31.2%

52